{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Skin+Tumor&page=2", "query": { "condition": "Malignant Skin Tumor", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Skin+Tumor&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-25T19:55:14.790Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04109482", "title": "Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)" ], "interventions": [ { "name": "MB-102", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Mustang Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2020-02-17", "completion_date": "2023-05-17", "has_results": false, "last_update_posted_date": "2024-07-22", "last_synced_at": "2026-06-25T19:55:14.790Z", "location_count": 4, "location_summary": "Duarte, California • Boston, Massachusetts • Durham, North Carolina + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04109482" }, { "nct_id": "NCT00238329", "title": "PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Intraocular Melanoma", "Melanoma (Skin)" ], "interventions": [ { "name": "PEG-interferon alfa-2b", "type": "BIOLOGICAL" }, { "name": "thalidomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2001-01", "completion_date": "2007-06", "has_results": false, "last_update_posted_date": "2013-04-08", "last_synced_at": "2026-06-25T19:55:14.790Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00238329" }, { "nct_id": "NCT01590069", "title": "Aerosolized Aldesleukin in Treating Patients With Lung Metastases", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Malignant Neoplasm in the Lung", "Metastatic Melanoma", "Metastatic Osteosarcoma", "Metastatic Renal Cell Cancer", "Sarcoma", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Stage IV Osteosarcoma AJCC v7", "Stage IV Renal Cell Cancer AJCC v7" ], "interventions": [ { "name": "Aerosolized Aldesleukin", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "12 Years to 50 Years" }, "enrollment_count": 70, "start_date": "2012-06-28", "completion_date": "2029-04-30", "has_results": false, "last_update_posted_date": "2026-04-21", "last_synced_at": "2026-06-25T19:55:14.790Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01590069" }, { "nct_id": "NCT06546553", "title": "A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Non-small-cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck", "Renal Cell Carcinoma", "Colorectal Carcinoma", "Ovarian Carcinoma" ], "interventions": [ { "name": "PF-07826390", "type": "DRUG" }, { "name": "sasanlimab", "type": "BIOLOGICAL" }, { "name": "SOC (anti-PD-1 + platinum -based chemo)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2024-09-06", "completion_date": "2025-10-03", "has_results": false, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-06-25T19:55:14.790Z", "location_count": 8, "location_summary": "Beverly Hills, California • Fort Myers, Florida • Orlando, Florida + 4 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06546553" }, { "nct_id": "NCT00991991", "title": "Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "polymorphism analysis", "type": "GENETIC" }, { "name": "matrix-assisted laser desorption/ionization time of flight mass spectrometry", "type": "OTHER" }, { "name": "medical chart review", "type": "OTHER" } ], "intervention_types": [ "GENETIC", "OTHER" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 5, "start_date": "2009-07", "completion_date": "2016-03", "has_results": false, "last_update_posted_date": "2016-05-17", "last_synced_at": "2026-06-25T19:55:14.790Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00991991" }, { "nct_id": "NCT01484015", "title": "Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Lymphoblastic Leukemia", "Adult Acute Myeloid Leukemia", "Adult Burkitt Lymphoma", "Adult Diffuse Large Cell Lymphoma", "Adult Diffuse Mixed Cell Lymphoma", "Adult Diffuse Small Cleaved Cell Lymphoma", "Adult Hodgkin Lymphoma", "Adult Immunoblastic Large Cell Lymphoma", "Adult Lymphoblastic Lymphoma", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Breast Cancer", "Chronic Eosinophilic Leukemia", "Chronic Lymphocytic Leukemia", "Chronic Myelogenous Leukemia", "Chronic Myelomonocytic Leukemia", "Chronic Neutrophilic Leukemia", "Cutaneous T-cell Non-Hodgkin Lymphoma", "Disseminated Neuroblastoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Grade 1 Follicular Lymphoma", "Grade 2 Follicular Lymphoma", "Grade 3 Follicular Lymphoma", "Malignant Testicular Germ Cell Tumor", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma", "Multiple Myeloma", "Mycosis Fungoides/Sezary Syndrome", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Neutropenia", "Nodal Marginal Zone B-cell Lymphoma", "Ovarian Epithelial Cancer", "Ovarian Germ Cell Tumor", "Plasma Cell Neoplasm", "Poor Prognosis Metastatic Gestational Trophoblastic Tumor", "Primary Myelofibrosis", "Prolymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Splenic Marginal Zone Lymphoma" ], "interventions": [ { "name": "cefepime hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2011-02", "completion_date": "2012-10", "has_results": false, "last_update_posted_date": "2018-07-18", "last_synced_at": "2026-06-25T19:55:14.790Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01484015" }, { "nct_id": "NCT03291938", "title": "IACS-010759 in Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Estrogen Receptor Negative", "HER2/Neu Negative", "Metastatic Malignant Solid Neoplasm", "Pancreatic Ductal Adenocarcinoma", "Progesterone Receptor Negative", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Prognostic Stage IV Breast Cancer AJCC v8", "Recurrent Lymphoma", "Refractory Lymphoma", "Stage II Pancreatic Cancer AJCC v8", "Stage IIA Pancreatic Cancer AJCC v8", "Stage IIB Pancreatic Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Triple-Negative Breast Carcinoma", "Unresectable Solid Neoplasm" ], "interventions": [ { "name": "Oxidative Phosphorylation Inhibitor IACS-010759", "type": "DRUG" }, { "name": "Pharmacodynamic Study", "type": "OTHER" }, { "name": "Pharmacokinetic Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2017-11-13", "completion_date": "2020-11-23", "has_results": false, "last_update_posted_date": "2020-11-24", "last_synced_at": "2026-06-25T19:55:14.790Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03291938" }, { "nct_id": "NCT01606748", "title": "A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Solid Tumor" ], "interventions": [ { "name": "Necitumumab", "type": "BIOLOGICAL" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2012-08", "completion_date": "2016-06", "has_results": true, "last_update_posted_date": "2019-09-30", "last_synced_at": "2026-06-25T19:55:14.790Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Detroit, Michigan • Las Vegas, Nevada + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01606748" }, { "nct_id": "NCT02129075", "title": "A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cutaneous Melanoma", "Melanoma", "Melanoma of Unknown Primary", "Mucosal Melanoma", "Ocular Melanoma", "Stage IIB Cutaneous Melanoma AJCC v6 and v7", "Stage IIC Cutaneous Melanoma AJCC v6 and v7", "Stage III Cutaneous Melanoma AJCC v7", "Stage IIIA Cutaneous Melanoma AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7" ], "interventions": [ { "name": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401", "type": "BIOLOGICAL" }, { "name": "Poly ICLC", "type": "DRUG" }, { "name": "Recombinant Flt3 Ligand", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2014-04-09", "completion_date": "2018-05-18", "has_results": true, "last_update_posted_date": "2021-11-16", "last_synced_at": "2026-06-25T19:55:14.790Z", "location_count": 7, "location_summary": "Chicago, Illinois • New York, New York • Durham, North Carolina + 3 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02129075" }, { "nct_id": "NCT01335009", "title": "Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "MORAb-004 (monoclonal antibody)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2011-05-16", "completion_date": "2020-04-10", "has_results": true, "last_update_posted_date": "2021-09-01", "last_synced_at": "2026-06-25T19:55:14.790Z", "location_count": 20, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 14 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01335009" } ] }